Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation. Hot Off the Press and into Your Practice: The Last Year in Medical News
|
|
- Eugenia Powell
- 6 years ago
- Views:
Transcription
1 Hot Off the Press and into Your Practice: The Last Year in Medical News Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Moyer VA, et al. Ann Internal Med. 2014;160(5): USPSTF Lung Cancer Screening Guideline Development Methods USPSTF Lung Cancer Screening: Systematic review Modeling Studies to estimate benefits and harms by age groups and screening frequencies Leading cause of cancer death in US men and women Older studies of CXR and sputum cytology for lung cancer screening found no benefit Benefits = Harms = Poorly characterized Prevention of lung cancer related deaths 95% of positive tests are false positives 10 12% of diagnosed cancers are cancers that would not have impacted the patient s health Radiation harms high in patients undergoing multiple screens Moyer VA, et al. Ann Internal Med. 2014;160(5): USPSTF Lung Cancer Screening: NLST Randomized Trial 53,000 smokers, 30 pack-years aged years Annual Low- Dose CT Annual CXR Lung Cancer Mortality Median 6.5 years 1.3% 1.6% Number-needed to screen: 333 to prevent 1 lung cancer death 2004 USPSTF stated that the evidence was insufficient to recommend for or against screening. Moyer VA, et al. Ann Internal Med. 2014;160(5): Aberle DR, et al. New Engl J Med. 2011;365(5): USPSTF Lung Cancer Screening: Major Recommendation (B Level) Annual screening in people age 55 to 80 who: Have at least a 30 pack-year smoking history Have actively smoked within the past 15 years Do not have limited life expectancy Would undergo curative lung surgery Note the recommendation to screen patients older than the oldest patients in the NLST, based on modeling studies. Moyer VA, et al. Ann Internal Med. 2014;160(5):
2 USPSTF Lung Cancer Screening: Screening is already happening Recommendation will continue what has already begun screening of heavy smokers Harms likely to outweigh benefits in other populations: Patients who quit smoking >15 years ago Patients with < 30 pack-year smoking history Patients < 55 years 25-Year Follow-up for Breast Cancer Incidence and Mortality of the Canadian National Breast Screening Study Moyer VA, et al. Ann Internal Med. 2014;160(5): Year Follow-up of Breast Cancer Screening The benefits and harms of breast cancer screening remain controversial. What are the long-term benefits and harms of breast cancer screening in women aged 40 to 59 years? 25-Year Follow-up of Breast Cancer Screening: Methods 89,835 women aged years Canadian National Breast Screening Study Randomized Trial of Mammography in 89,835 Women Age years Age years 5 years Yearly Mammogram + Breast Exam Initial Breast Exam, No Yearly Screening Yearly Mammogram + Breast Exam Yearly Breast Exam Alone Follow-Up: Mean 21.9 years *All breast exams performed by trained nurses and took approximately 10 min. 25-Year Follow-up of Breast Cancer Screening: Results 25-Year Follow-up of Breast Cancer Screening: Results (cont.) Screening Period Follow Up Impact of screening on death from cancer diagnosed in screening period: Intervention (n=44,925) Cancers diagnosed Node + cancers Palpable cancers Cancers diagnosed 666 (1.5%) 204 (0.45%) 454 (1.0%) 2584 (5.8%) Hazard Ratio Confidence Interval Overall to 1.30 Age years to 1.49 Age years to 1.36 All-Cause Mortality 10.6% in both groups Control (n=44,910) 524 (1.2%) 170 (0.38%) 524 (1.2%) 2609 (5.8%) At 15 years, 106 excess cancers in the screened group, implying that 22% of screen-detected cancers represented over-diagnosis
3 25-Year Follow-up of Breast Cancer Screening Mammography does not impact long-term mortality Women in their 50s in control group received annual 10-min breast exams, study used older technology, intervention was only 5 years 1/5 of breast cancers found during screening represent over-diagnosis Estimate of overdiagnosis helpful for patient counseling Not likely to fundamentally change screening practice in US 2013 ACC/AHA Guideline on the Treatment of to Reduce Atherosclerotic Cardiovascular Risk in Adults Stone NJ, et al. J Am Coll Cardiol (Nov 7); Epub ahead of print ACC/AHA Guideline: Treatment of and Methods Resulted from the NHLBI s decision to no longer issue guidelines Evidence reviews completed by NHLBI-appointed panels Rated for quality of evidence and strength of recommendation Focused around key questions ACC/AHA Guideline: Treatment of Assess risk for atherosclerotic cardiovascular disease in all patients Major Recommendations Use a tool to assess riskrecommended using a calculator based on the pooled cohort equations Statin therapy and intensity of statin therapy based on risk for atherosclerotic cardiovascular disease (no more concept of goal LDL ) ACC/AHA Guideline: Treatment of Blood Cholesterol Gender Male Age 59 Race African American Total Cholesterol 185 HDL Cholesterol 55 Systolic Blood Pressure Hypertension Treatment Diabetes Smoker 130 No Yes No Based on the data entered (assuming no clinical CVD and LDL C mg/dl) Consider high intensity statin Moderate intensity statin therapy should be initiated or continued in adults aged years with DM (1A) High intensity statin therapy is reasonable for adults aged years with DM and 7.5% estimated 10 year ASCVD risk unless contraindicated (IIaB) ACC/AHA Guideline: Treatment of Statin Intensity High Moderate Low Patients to Receive Age <75 with: CVD, estimated 10 year CVD risk 7.5%, LDL >190 mg/dl Age 75 with: CVD, DM with 10 year CVD risk <7.5% Patients who do not tolerate higher intensity therapy Drugs Atorvastatin mg Rosuvastatin mg Atorvastatin mg Rosuvastatin 5 10 mg Simvastatin mg Pravastatin mg Lovastatin 40 mg Simvastatin 10 mg Pravastatin mg Lovastatin 20 mg
4 ACC/AHA Guideline: Treatment of Areas of Controversy Risk assessment calculator is new and seems to overestimate risk compared to other validated tools (like Framingham calculator) Is 7.5% risk the right threshold at which to recommend highintensity statin therapy? Adherence to new guideline will likely result in statin therapy for more patients but checking lipids less frequently since no need to worry about reaching lipid goals ACC/AHA Guideline: Treatment of Clinical Bottom Line Perform risk assessment using tool of your choice (Framingham is a good option) Target statin intensity to risk Major paradigm shift away from goal LDL and toward treating high-risk patients with more intensive statin therapy Details may change but paradigm likely to be retained Combined strategy may emerge, with risk-based care and target- LDL-based care for patients with very high cholesterols New U.S. Hypertension Guidelines: Finding Order in the Chaos Go AS, et al. Hypertension (Nov 15); Epub ahead of print. James PA, et al. JAMA. 2014;311(5): U.S. Hypertension Guidelines: The Back Story 2008 Jun 2013 Nov 2013 JNC-8 panel convened by NHLBI Formalized guideline development process and conducted a detailed systematic review, rating the quality of all evidence NHLBI announced withdrawal from guideline generation ACC/AHA would take over hypertension and lipid guidelines; JNC-8 guideline was complete and under review 2 separate guidelines published because JNC-8 panelists opted not to collaborate with ACC/AHA U.S. Hypertension Guidelines: 2 Separate Guidelines AHA/ACC/CDC Science Advisory: An Effective Approach to High Blood Pressure Control Essentially a simple algorithm Plan to follow-up with a full guideline in Evidence-Based Guideline for the Management of High Blood Pressure in Adults (from the panel members appointed to JNC8 ) A full guideline, but not endorsed by any formal organization Adheres to current standards for evidence assessment and transparency Go AS, et al. Hypertension (Nov 15); Epub ahead of print. James PA, et al. JAMA. 2014;311(5): U.S. Hypertension Guidelines: Similarities and Differences Goal blood pressure First line agents (general population) Special populations Treatment thresholds JNC 8 Panelists <150/90 in patients aged 60 without DM or CKD; 140/90 in everyone else Non black: thiazide, CCB, ACE I, or ARB Black: thiazide or CCB DM: same as general population CKD: include an ACE I or ARB Not specified Go AS, et al. Hypertension (Nov 15); Epub ahead of print. James PA, et al. JAMA. 2014;311(5): AHA/ACC/CDC <140/90 ( may be lower for some patients ) Thiazide first line Additional agents: ACE I, ARB, CCB DM: ACE I or ARB, thiazide, CCB, β blocker CKD: ACE I or ARB (others mentioned as well) BP <160/100: trial of lifestyle ±thiazide SBP 160 or DBP 100: lifestyle plus 2 drugs (thiazide + ACE I, ARB, or CCB)
5 U.S. Hypertension Guidelines Areas of Consensus Goal BP: 140/90 for most patients, regardless of comorbidities Tolerate higher BP in patients with DM and probably CKD (especially if there are side effects) First line agents: Thiazide ACE-I ARB CCB Take β-blockers off the list of first-line agents Do NOT use β-blocker as firstline agent (for hypertension) Wait for the next round in 2015! Chlorthalidone vs. Hydrochlorothiazide for the Treatment of Hypertension in Older Adults: A Population-based Cohort Study Dhalla IA, et al. Ann Intern Med. 2013;158(6): Go AS, et al. Hypertension (Nov 15); Epub ahead of print. James PA, et al. JAMA. 2014;311(5): Chlorthalidone vs. Hydrochlorothiazide For Treatment of Hypertension in Older Adults Some evidence suggests chlorthalidone is superior to hydrochlorothiazide (HCTZ) for preventing complications of hypertension, but the evidence is inconclusive. Dhalla IA et al. Annals Int Med. 2013; 158(6): What are the relative safety and effectiveness of chlorthalidone and HCTZ for treating hypertension in older adults? Chlorthalidone vs. Hydrochlorothiazide: Methods Retrospective Population-Based Cohort Study in Ontario Patients aged 66+ newly prescribed either drug 1993 to 2010 Identified through multiple province-wide databases Dhalla IA, et al. Ann Intern Med. 2013;158(6): Matched patients receiving each drug for baseline characteristics Excluded patients with major comorbidities (MI, CVA, etc) to find those with primary hypertension Primary outcome: death, or hospitalization for MI, heart failure or stroke Chlorthalidone vs. Hydrochlorothiazide: Results Chlorthalidone vs. Hydrochlorothiazide Chlorthalidone N = 10,384 vs HCTZ N = 19,489 Some baseline differences adjusted for in the analysis Both drugs have similar efficacy for preventing complications of hypertension. Chlorthalidone may lead to more hypokalemia and possibly hyponatremia. Patients receiving chlorthalidone (vs. HCTZ) had: Adjusted HR (CI) Similar rates of primary outcome 0.93 (0.81 to 1.06) Higher rates of hypokalemia 3.06 (2.04 to 4.58) Higher rates of hyponatremia 1.68 (1.24 to 2.28) Dhalla IA, et al. Ann Intern Med. 2013;158(6): Implications for practice Either drug can be used for blood pressure control. Monitor for hypokalemia with either drug, but note this may be worse with chlorthalidone. Dhalla IA, et al. Ann Intern Med. 2013;158(6): Since other studies have shown chlorthalidone more effective, a randomized trial may be needed.
6 Use of Azithromycin and Death from Cardiovascular Causes Use of Azithromycin and Death from Cardiovascular (CV) Causes Observational study in Medicaid beneficiaries Azithromycin associated with 2-3 times higher risk for CV death compared to other antibiotics (small absolute risk) Called into question the safety of this commonlyprescribed antibiotic Is azithromycin associated with increased risk for death from cardiovascular causes, compared with penicillin or no antibiotic, in a population-based sample. Use of Azithromycin and Death from Cardiovascular Causes: Methods Demographic and clinical information from Danish Civil Registration System All people aged living in Denmark Population-Based Cohort Study National prescription registry National register of causes of death Defined population who used azithromycin, penicillin V, or no antibiotics (control), incl. timing of treatment Propensity scores to stratify patients by overall risk, but unable to adjust for some cardiac risk factors Use of Azithromycin and Death from Cardiovascular Causes: Results Episodes of Use Azithromycin: 1.1 million Penicillin: 7.4 million No antibiotics: 7.1 million Baseline Differences Many differences across treatment groups Adjusted for in analysis Risk of CV Death Low overall, much lower than in study that found increased risk with azithromycin Matched Propensity Score Analysis Current use of azithromycin increased risk of CV death compared to no antibiotics RR: 2.85 (CI, 1.13 to 7.24) Likely reflects risk associated with infection Use of Azithromycin and Death from Cardiovascular Causes In a generally healthy population, azithromycin did not increase the risk for CV death compared to penicillin. SSRI Use During Pregnancy and Risk of Stillbirth and Neonatal Mortality Azithromycin probably safe in patients otherwise at low risk for CV events. To minimize risk and optimize care, avoid unnecessary antibiotic use. Consider avoiding azithromycin in patients at increased risk for CV events and when alternative antibiotics are effective.
7 SSRI Use During Pregnancy and Risk of Stillbirth and Neonatal Mortality The use of SSRIs during pregnancy remains controversial, though SSRI continuation in women who become pregnant is increasingly common. Does the use of SSRIs during pregnancy increase the risk for stillbirth or neonatal mortality? SSRI Use During Pregnancy and Risk of Stillbirth and Neonatal Mortality: Study Design Retrospective Population-Based Cohort Study in Denmark Fertility database ( ) Data on pregnancies and births Prescription database Identified exposure to citalopram, escitalopram, fluoxetine, paroxetine, or sertraline during each trimester of pregnancy* Outcomes: Stillbirth Neonatal mortality (death within 28 days of birth) Adjusted for other prognostic factors in multivariate analysis *other SSRIs were very rare SSRI Use During Pregnancy and Risk of Stillbirth and Neonatal Mortality: Results Cohort: 920,620 pregnancies SSRI Exposure: 1.3% of pregnancies Neonatal Mortality: 0.34% Stillbirth 0.43% Trimester of exposure otherwise did not impact risk Not associated with SSRIs overall OR 1.14 (CI, ) Associated with citalopram in 3 rd trimester OR 2.13 (CI, ) Not associated with SSRIs overall OR 1.19 (CI, ) or with individual drugs SSRI Use During Pregnancy and Risk of Stillbirth and Neonatal Mortality SSRI use overall does not appear to increase rates of stillbirth or neonatal mortality. Prudent to avoid citalopram, escitalopram (closely related to citalopram), and paroxetine* during pregnancy. *associated with congenital malformations in other studies Citalopram may be specifically associated with neonatal mortality, though only with exposure throughout pregnancy. Sertraline and fluoxetine likely safe in pregnant women in whom medication for depression is needed. Combined Angiotensin Inhibition for Treatment of Diabetic Nephropathy Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy Combination therapy with ACE-inhibitors and angiotensin receptor blockers (ARBs) can decrease proteinuria, but may increase complications, such as renal failure and hyperkalemia. Does combination therapy with an ARB and ACE-inhibitor slow the progression of diabetic nephropathy compared with an ARB alone?
8 Combined Angiotensin Inhibition for Treatment of Diabetic Nephropathy: Methods Randomized Trial at VA Hospitals 1448 veterans Type 2 diabetes + GFR 30 to 90 ml/min/1.73 m 2 + Micro- or macroalbuminuria Losartan 100 mg/day plus placebo Losartan 100 mg/day plus lisinopril mg/d Primary endpoint: First occurrence of GFR decline, ESRD, or death Note: Study had industry funding and involvement. Combined Angiotensin Inhibition for Treatment of Diabetic Nephropathy: Results Study stopped early (after median 2.2 years) due to increased adverse events in the combination therapy group Endpoint Combination Group ARB Alone group P value Number needed to harm Primary outcome 18.2% 21.0% 0.30 NA (efficacy) Serious adverse 57.5% 52.5% 0.06 NA events Acute kidney injury 18.0% 11.0% < Hyperkalemia 9.9% 4.4% < Combined Angiotensin Inhibition for Treatment of Diabetic Nephropathy Combination therapy with ACE-inhibitor and ARB Did not improve outcomes compared to an ARB alone in patients with diabetic nephropathy Led to higher rates of hyperkalemia and acute kidney injury Effect of Vitamin E and Memantine on Functional Decline in Alzheimer s Disease: The TEAM-AD VA Cooperative Randomized Trial Do not use combination of ACE-inhibitors and ARBs to prevent progression in patients with diabetic nephropathy. Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease Vitamin E and memantine may slow disease progression in moderate-severe Alzheimer s dementia, but effects in mild-moderate dementia are unclear What are the effects of vitamin E, memantine, or both on functional decline in patients with mild-moderate Alzheimer s disease who are already on an acetylcholinesterase inhibitor? Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: Methods Randomized, Blinded Trial of Veterans with Alzheimer Disease Veterans with MMSE* while on an acetylcholinesterase inhibitor Vitamin E 2000 IU/d plus memantine placebo Memantine 20 mg/d plus vitamin E placebo Vitamin E plus memantine Placebo vitamin E and placebo memantine Primary Outcome Score on ADCS-ADL Inventory** Validated score : 0 to 78 Lower score worse 2-point difference is clinically meaningful *Mini Mental State Exam **Alzheimer Disease Cooperative Study-Activities of Daily Living
9 Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease: Results 613 patients randomized (97% men) Mean follow-up: 2.7 years Dropout rate: 42% Similar across groups; 50% due to death Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease Memantine did not slow progression of mildmoderate disease but did have adverse effects. Vitamin E slowed progression of disease slightly. Slower rate of decline in ADCS-ADL scores for vitamin E than placebo (difference 3.15 points) Rates of decline for memantine and combination did not differ from placebo. Memantine groups had higher rates of infection or infestation than placebo Do not use memantine with an acetylcholinesterase inhibitor to slow disease progression in mildmoderate Alzheimer s disease. If patients or families request additional therapy, use vitamin E. Regardless of therapy, Alzheimer s disease is progressive and effect of treatment is small.
Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation. Hot Off the Press and into Your Practice: The Last Year in Medical News
Presenter Disclosure Information 1:45 3pm Hot Off the Press and Into Your Practice 2014 The following relationships exist related to this presentation: Michael J. Bloch, MD, FACP, FASH, receives consulting
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH SCIENTIFIC DIRECTOR KIDNEY HEALTH RESEARCH COLLABORATIVE - UCSF CHIEF - GENERAL INTERNAL MEDICINE, SAN FRANCISCO
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationTo Do or Not To Do? The Annual Physical- Beyond The PAP And Breast Exam
1/27/2015 To Do or Not To Do? The Annual Physical- Beyond The PAP And Breast Exam Fleur Sack, M.D., FAAFP Society of General Internal Medicine Cochrane review of 182,000 people followed for 9 years : the
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationUpdates in Cardiovascular Recommendations for Diabetic Patients
Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationBest Practices in Cardiac Care: Getting with the Guidelines
Best Practices in Cardiac Care: Getting with the Guidelines December 9, 2014 Agenda Cardiovascular Disease: How do the guidelines fit into an implementation scheme? What the guidelines set out to accomplish
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationSpeaker Disclosure. Pharmacist Objectives. Path to New Hypertension (HTN) Guidelines. Overview of New HTN Guidelines 8/21/2014
Speaker Disclosure Erica Pearce, Pharm.D. declares no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants,
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationApplying the Intricacies of the New Hypertension and Lipid Guidelines to Your Patients
Applying the Intricacies of the New Hypertension and Lipid Guidelines to Your Patients Joe Anderson, PharmD, PhC, BCPS James Nawarskas, PharmD, PhC, BCPS Gretchen Ray, PharmD, PhC, BCACP University of
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationDisclosures. Outline. Outline 5/23/17 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More information2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004
Perspectives on the 2013 ACC/AHA Cholesterol Guidelines Donald M. Lloyd-Jones, MD ScM Senior Associate Dean Chair and Professor of Preventive Medicine Northwestern Feinberg School of Medicine Disclosures
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationNew Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine
New Clinical Trends in Geriatric Medicine April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine Objectives Review current guidelines for blood pressure (BP) control in older adults
More informationDisclosures. Outline. Outline 7/27/2017 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationThiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14
Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance
More informationDrugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events
Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events How does all this play out when it comes to treating patients with type 2 DM who have chronic kidney disease? Therapeutic
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationUpdate in Outpatient Medicine JNC 8, Hypertension and More
Update in Outpatient Medicine JNC 8, Hypertension and More March 6 th 2015 Robert Gluckman, MD, FACP CMO Providence Health Plans Disclosures Stock Holdings Abbott Labs Abbvie Bristol Myers Squibb GE Proctor
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More information